AbbVie (ABBV) Looks to Deepen Its Push Into Rapidly Growing Obesity-Treatment Market

AbbVie Inc. (NYSE:ABBV) is 1 of the 10 Goldman Sachs undervalued stocks to put in.

On January 14, 2026, Reuters reported that AbbVie Inc. (NYSE:ABBV) is looking to deepen its propulsion into the rapidly increasing obesity-treatment market, outlining its plans astatine the JPMorgan Healthcare Conference. The company’s plans halfway connected GUBamy, an amylin-mimetic weight-loss cause licensed from Danish biotech Gubra. Emphasizing differentiation alternatively than a first-mover strategy, the company’s absorption highlighted that existing first-generation GLP-1 therapies airs problems related to tolerability and durability. These shortcomings thrust precocious diligent drop-off rates, absorption noted.

In opposition to GLP-1 drugs similar Novo Nordisk’s Wegovy oregon Eli Lilly’s Zepbound, amylin-based therapies purpose to replicate a pancreas-derived hormone that reduces appetite and slows gastric emptying. Furthermore, archetypal studies amusement that these drugs assistance sphere musculus wide portion promoting value loss. Thus, AbbVie Inc. (NYSE:ABBV) believes patients whitethorn beryllium much apt to enactment connected attraction longer. Management appears optimistic astir capitalizing connected the market, projected to make astir $150 cardinal successful yearly income implicit the adjacent decade.

AbbVie Inc. (NYSE:ABBV) besides aims to leverage the overlap betwixt cosmetic and weight-loss patients connected the backmost of its established aesthetics franchise. With this, the institution could integrate attraction models for much businesslike lawsuit engagement.

AbbVie Inc. (NYSE:ABBV), a research-based biopharmaceutical company, develops therapies crossed immunology, oncology, neuroscience, virology, aesthetics, and metabolic diseases. The institution leverages diversified pipelines and planetary commercialization capabilities, driving durable maturation and innovation.

While we admit the imaginable of ABBV arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 7 Best Rising Tech Stocks to Buy Now and 12 Best Multibagger Stocks to Buy Heading into 2026.

Disclosure: None.